It may cause dynamic obstruction to LV outflow and LV filling ... In the form of asymmetrical septal hypertrophy known as idiopathic hypertrophic subaortic stenosis, the proximal septal ...

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...

Aficamten, targeted at obstructive hypertrophic cardiomyopathy (oHCM), has completed NDA submissions in the U.S. and China, with further submissions expected in Europe. This demonstrates the company’s ...

Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

The patient was diagnosed with Hypertrophic Obstructive Cardiomyopathy (HOCM), a genetic heart condition that led to severe ...

The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...

Hypertrophic cardiomyopathy (HCM ... This paper presents a case study of a 53-year-old female with a dynamic and obstructive form of HCM. The study includes a case presentation, clinical findings ...